SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 7, 2014) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has ...

Johnson & Johnson said Tuesday it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company in South San Francisco that is working on treatments for viral diseases. Alios is ...

Johnson & Johnson has abandoned development of anti-RSV drug AL-8176, wiping another $900 million off the value of the assets it acquired from Alios Biopharma. The writedown comes months after J&J ...

Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C ...

SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 30, 2014) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, today announced a definitive agreement ...

SOUTH SAN FRANCISCO, CA– May 30, 2013 – Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory ...

Alibaba has bought a stake in a Chinese microprocessor manufacturer to promote development of of processors which support Alibaba’s operating system – AliOS. AliOS has two flavours – called AliOS ...

Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The ...

Aim is to combine ALS-2200 and ALS-2158 with approved Incivek and investigational candidate VX-222. Vertex Pharmaceuticals is paying Alios BioPharma $60 million up front for worldwide rights to two of ...